Psychopharmacology of olanzapine. A review

British Journal of Psychiatry

Volumn 174, Issue MAY SUPPL. 38, 1999, Pages 52-58

  Stephenson, C M E ^a   Pilowsky, L S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; CLOZAPINE; CYTOCHROME P450; DOPAMINE 2 RECEPTOR; HALOPERIDOL; HISTAMINE RECEPTOR; MUSCARINIC RECEPTOR; OLANZAPINE; PLACEBO; PROLACTIN; RISPERIDONE; SEROTONIN 2A RECEPTOR; DRUG DERIVATIVE; NEUROLEPTIC AGENT; PIRENZEPINE;

AGRANULOCYTOSIS; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; HYPERPROLACTINEMIA; NEGATIVE SYNDROME; PSYCHOPHARMACOLOGY; QUALITY OF LIFE; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; TARDIVE DYSKINESIA; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; HUMANS; PIRENZEPINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0032922635     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/s0007125000298115     Document Type: Review

References (61)

1. Andreasen, N. C. (1981) Scale for the Assessment of Negative Symptoms (SANS). Iowa City. IA: University of Iowa.
2. Bakshi, V. P. & Geyer, M. A. (1995) Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology, 122, 198-201.
3. Baldacchino, A. M., Stubbs, J. H. & Nevison-Andrews, D. (1997) The use of olanzapine in non-compliant or treatment-resistant olozapine population in hospital. Pharmaceutical Journal, 260, 207-209.
4. Baldwin, D. S. & Montgomery, S. A. (1995) First clinical experience with olanzapine (IY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. International Clinical Psychopharmacology, 10, 239-244.
5. Beasley, C. M., Jr., Sanger, T., Saterlee, W., et al (1996a) Olanzapine vs placebo: results of a double-blind fixed dose olanzapine trial. Psychopharmacology (Berlin), 124, 159-167.
6. _ , Tollefson, G., Tran, P., et al (1996b) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 111-123.
7. _ , _ &. (1997a) Efficacy of olanzapine: an overview of pivotat clinical trials. Journal of Clinical Psychiatry, 58 (suppl. 10), 7-12.
8. _ , _ & _ . (1997b) Safety of olanzapine. Journal of Clinical Psychiatry, 58 (suppl. 10), 13-17.
9. _ , Hamilton, S. Y., Crawford, A. M., et al (1997c) and the Olanzapine E003 Study Group Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology, 7, 125-137.
10. Bergstrom, R. F., Callaghan, J. T., Cerimele, B. J., et al (1995) Pharmacokinetics of olanzapine in elderly and young (abstract). Pharmaceutical Research, 12 (suppl), 5358.
11. Boyd, D., Obermeyer, B. D., Nyhart, E. H., Jr., et al (1993) The disposition of olanzapine in healthy volunteers (abstract no. 120). Pharmocologist, 35, 176.
12. Bymaster, F. P., Calligaro, D. O., Falcone, J. F., et al (1996a) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14, 87-96.
13. +-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology, 124, 87-94.
14. _ , Rasmussen, K., Calligaro, D. O., et al (1997) In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. Journal of Clinical Psychiatry, 58 (suppl. 10), 28-36.
15. Chiodo, L. A. & Bunney, B. S. (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. Journal of Neuroscience, 3, 1607-1619.
16. Cools, A. R., Prinssen, E. P. M. & Ellenbroek, B. A. (1995) The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothiphendyl, ORG 5222, sertindole, olanzapine. Psychopharmacology, 119, 428-139.
17. Corbett, R., Camacho, F., Woods, A.T., et al (1995) Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviours. Psychopharmacology, 120, 67-74.
18. Deutch, A.Y., Moghaddam, B., Innis, R. B., et al (1991) Mechanisms of action of atypical antipsychotic drugs. Schizophrenia Research, 4, 121-156.
19. _ , Lee, M. C. & Iadarola, M. J. (1992) Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Molecular and Cellular Nouroscience, 3, 32-341.
20. 2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Proceedings of the National Academy of Sciences of the United States of America, 89, 4270-4272.
21. Endicott, J., Spitzer, R. L., Fleiss, J. L., et al (1976) The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbances. Archives of General Psychiatry, 33, 766-771.
22. 2 receptor blockade to haloperidol. Neuroscience Letters, 194, 77-80.
23. Fuller, R.W. & Snoddy, H. D. (1992) Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine, an antipsychotic drug candidate. Research Communications in Chemical Pathology and Pharmacology, 77, 87-93.
24. Gleason, S. D. & Shannon, H. E. (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine, and serotonin receptor subtype selective antagonists in mice. Psychopharmacology, 129, 79-84.
25. Guy, W. (1976) ECDLU Assessment Manual for Psychopharmacology (Revised DHEW Pub. (ADM)). Rockville, MD: National Institute for Mental Health.
26. Kane, J. M., Honigfeld, G., Singer, J., Meltzer, H. & the Clozaril Collaborative Study Group (1988) Olozapine for the treatment resistant schizophrenic. Archives of General Psychiatry, 45, 789-796.
27. Kapur, S. & Remington, G. (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry, 153, 466-476.
28. Kassahun, K., Mattluz, E., Nyhart, E. Jr, et al (1997) Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metabolism and Disposition, 25, 81-93.
29. Kay, S. R., Fiszbein, A., Opler, L. A. (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
30. Kerwin, R.W. (1994) The new atypical antipsychotics. British Journal of Psychiatry, 164, 141-148.
31. Launer, M. A. (1997) High dose olanzapine in treatment resistant schizophrenia. Schizophrenia Research, 29, 150.
32. Lieberman, J. A. (1996) Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. Journal of Clinical Pharmacology, 57 (suppl. II), 68-71.
33. Martin, J., Gomez, J.-C., Garcia-Bernado, E., et al (1997) Olanzapine in treatment-refractory schizophrenia: results of an open label study. The Spanish Group for the Study of Olanzapine inTreatment-Refractory Schizophrenia. Journal of Clinical Psychiatry, 58, 479-483.
34. 2A receptors. British Journal of Pharmacology, 114, 153P.
35. Montgomery, S. A. & Asberg, M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389.
36. Moore, N. A., Tye, N. C., Axton, M. S., et al (1992) The behavioural pharmacology of olanzapine, a novel "atypical" antipsychotic agent. Journal of Pharmacology and Experimental Therapeutics, 262, 545-551.
37. _ , Calligaro, D. O., Wong, D.T., et al (1993) The pharmacology of olanzapine and other new antipsychotic agents. Current Opinion in Investigational Drugs, 2, 281-293.
38. _ , Leander, D., Benvenga, M. J., et al (1997) Behavioural pharmacology of olanzapine: a novel antipsychotic drug. Journal of Clinical Psychiatry, 58 (suppl. 10), 37-44.
39. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology, 16, 78-84.
40. Overall, J. & Gorman, D. E. (1962) The Brief Psychiatric Rating Scale. Psychological Report, 10, 799-812.
41. Patel, B. R., Nyhart, E. L. Jr., Callaghan, J. T., et al (1995) Combined population pharmacokinetic analysis of olanzapine in healthy volunteers (abstract). Pharmaceutical Research, 12 (suppl.), S360.
42. 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet, 340, 199-202.
43. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology, 124, 148-153.
44. _ , Mulligan, R. S., Acton, P. D., et al (1997) Limbic selectivity of clozapine. Lancet, 350, 490-491.
45. Ratakonda, S., Miller, C. E., Gorman, J. M. & Sharif, Z. A. (1997) Efficacy of a 12 week trial of olanzapine in treatment refractory schizophrenia or schizoaffective disorder. Schizophrenia Research, 29, 150.
46. Ring, B. J., Catlow, J., Lindsay, T. J., et al (1996a) Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. Journal of Pharmacology and Experimental Therapeutics, 276, 658-666.
47. _ , Binkley, S. N., Vanderbranden, M., et al (1996b) In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. British Journal of Clinical Pharmacology, 41, 181-186.
48. Robertson, G. S. & Fibiger, H. C. (1992) Neuroleptics increase c fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience, 46, 315-328.
49. _ , Matsamura, H. & Fibiger, H. C. (1994) Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. Journal of Pharmacology & Experimental Therapeutics, 271, 1058-1066
50. _ & Fibiger, H. C. (1996) Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology, 14, 105-110.
51. 3 receptors is not shared by its two major metabolites and by structurally related and unrelated atypical neuroleptics. Nounyn Schmiedebergs Archives of Pharmacology (Berlin), 353, 290-294.
52. Sheitman, B. B., Lindgren, J. C., Early, R. P. H., et al (1997) High-dose olanzapine for treatment-refractory schizophrenia. American Journal of Psychiatry, 154, 1626.
53. Stockton, M. E. & Rasmussen, K. et al (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology, 14, 97-104
54. Tollefson, G., Beasley, C. M. Jr, Timura, R. N., et al (1997a) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry, 154, 1248-1254.
55. _ , _ & Tran, P. (1997b) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 157-465.
56. Tran, P.V., Dellva, M. A. & Tollefson, G. D. (1998) Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. British Journal of Psychiatry, 172, 499-505.
57. _ , _ , _ , et al (1991a) Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of Clinical Psychiatry, 58, 205-211.
58. _ , Hamilton, S. H., Kuntz, A. J., et al (1997b) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 17, 407-418.
59. 2a occupancy in vivo and response to the new atypical antipsychotics olanzapine and sertindole (letter). British Journal of Psychiatry, 171, 290-291.
60. Weaver, M. G. (1997) Olanzapine - pharmacology and clinical evaluation of a new atypical antipsychotic. Journal of Serotonin Research, 4, 145-157.
61. White, F. J. & Wang, R.Y. (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science, 221, 1054-1057.